Journal of Practical Oncology ›› 2022, Vol. 36 ›› Issue (1): 44-48.doi: 10.11904/j.issn.1002-3070.2022.01.008

• Clinical Research • Previous Articles     Next Articles

High expression of HPIP in endometrial carcinoma and its significance in the analysis of survival and prognosis

WANG Yuping, SI Meili, SUN Xiaoxia, GUO Yulin   

  1. The Second Hospital of Yulin City,Yulin 719000,China
  • Received:2021-07-13 Revised:2021-10-27 Online:2022-02-28 Published:2022-01-21

Abstract: Objective The aim of this study was to investigate the expression of hematopoietic pre-B-cell leukemia transcription factor(PBX)-interacting protein(HPIP)in normal endometrial tissues,endometrial atypical hyperplasia tissues and endometrial cancer tissues,and its clinical prognostic significance.Methods Immunohistochemical method was used to detect the expression of HPIP protein in 26 normal uterine endometrial tissues,30 endometrial atypical hyperplasia tissues and 122 endometrial cancer tissues.The correlation amongst the expression of HPIP in endometrial cancer tissues and its clinicopathological factors,disease-free survival(DFS)and overall survival(OS)were analyzed.Results The expression of HPIP in normal endometrial tissues and endometrial atypical hyperplasia tissues was significantly lower than that in endometrial cancer tissues,normal endometrial tissues and endometrial atypical hyperplasia tissues,the differences were statistically significant(P<0.05).The expression of HPIP in endometrial cancer tissues was closely related to its histological grade,federation international of gynecology and obstetrics(FIGO)staging and lymph node metastasis(P<0.05).Endometrial cancer patients with high expression of HPIP had significantly shorter DFS and OS than those with low expression of HPIP(P<0.05).Conclusion HPIP protein may be a very valuable biomarker,which can be used to interfere with the prognosis of patients with endometrial cancer,and may be used as a potential target for cancer treatment of endometrial cancer.

Key words: HPIP, Endometrial cancer, Immunohistochemistry, Clinical prognosis

CLC Number: